Company: NCEL
Filing Date: 2025-01-16
Form Type: 425
Source: 0001213900-25-004028
Chunk: 3

Company: NewcelX Ltd.
Filing Date: 2025-01-16
Form: 425
Chunk 3
---

statements pursuant to U.S. Federal securities laws. For example, NLS and Kadimastem are using forward-looking statements when they discuss
the expected closing of the transaction and the potential benefits of the transaction to NLS and Kadimastem and their respective shareholders,
as well as the expected strategic position of the combined company following the merger, if completed. These forward-looking statements
and their implications are based on the current expectations of the management of NLS and Kadimastem and are subject to a number of factors
and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following
factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: risks related
to the companies’ ability to complete the merger on the proposed terms and schedule, including risks and uncertainties related to
the satisfaction of the closing conditions related to the merger agreement and risks and uncertainties related to the failure to timely,
or at all, obtain shareholder approvals for the transaction; unexpected costs, charges or expenses resulting from the transaction and
potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed merger;
changes in technology and market requirements; either or both companies may encounter delays or obstacles in launching and/or successfully
completing their clinical trials; the companies’ products may not be approved by regulatory agencies; their technologies may not
be validated as they progress and their methods may not be accepted by the scientific community; either of both of the companies may be
unable to retain or attract key employees whose knowledge is essential to the development of their products; unforeseen scientific difficulties
may develop with the products being advanced by the companies; their products may wind up being more expensive than anticipated; results
in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate
with the results of human clinical trials; the companies’ patents may not be sufficient; their products may harm recipients; changes
in legislation may adversely impact either or both of the companies; inability to timely develop and introduce new technologies, products
and applications; and loss of market share and pressure on pricing resulting from competition, which could cause the actual results or
performance of candidate products to differ materially from those contemplated in such forward-looking statements. Except as otherwise
required by law, neither Kadimastem nor NLS undertakes any obligation to publicly release any revisions to these forward-looking statements
to reflect events or circumstances after the date